- Home
- / Aligos Therapeutics
Aligos Therapeutics
Stock Price
$9.4
2024-10-29
Market Capitalization
$28.8 M
2024-10-29
Revenue
$3.6 M
FY, 2024
Aligos Therapeutics Summary
Company Summary
- Overview
- Aligos Therapeutics is a company that develops curative therapies for hepatologic diseases and viral infections. It discovers and develops compounds that interact with disease-causing molecules such as viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- South San Francisco, CA, US | view all locations
- Website
- https://www.aligos.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Sushmita M. Chanda, Executive Vice President, Translational Safety Sciences
John Fry, Executive Vice President Clinical Development
Matthew W. McClure, Executive Vice President Chief Medical Officer
Operating MetricsView all
Discovery Projects
2
Q2, 2020
Pre-Clinical Phase Products
4
Q2, 2020
Phase I Trials Products
1
Q2, 2020
LocationsView all
2 locations detected
South San Francisco, CA HQ
United States
1 Corporate Dr 2nd floor
Leuven, Vlaanderen
Belgium
Gaston Geenslaan 1/building 3
Aligos Therapeutics Financials
Summary Financials
- Revenue (FY, 2024)
- $3.6M
- Net income (FY, 2024)
- ($131.2M)
- Cash (FY, 2024)
- $37.0M
- EBIT (FY, 2024)
- ($89.2M)
- Enterprise value
- ($4.7M)